Internal Medicine, Hematology & Oncology · Oak Lawn, IL
NPI
1710072624
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
4400 W 95th St, Suite 311
Oak Lawn, IL, 60453
Phone (708) 424-9710
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.5M
160,251 services
Medicare patients, 2024
557
Average age 75
Drug cost, 2024
$6.4M
1,702 prescriptions
Company payments, 2025
$4,801
From 55 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rami Y Haddad was code J1439 (injection, ferric carboxymaltose, 1 mg), 25,500 times for 25 patients. In total Rami Y Haddad billed 160,251 services in 132 codes, and Medicare paid $3.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-07-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 25,500 | 25 | $0.88 | $22K |
| J9119 Injection, cemiplimab-rwlc, 1 mg | Office | 14,700 | 11 | $21.67 | $319K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 14,000 | 19 | $44.77 | $627K |
| J0897 Injection, denosumab, 1 mg | Office | 9,540 | 59 | $20.47 | $195K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 9,080 | 17 | $2.28 | $21K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 4,356 | 14 | $21.39 | $93K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,190 | 38 | $0.09 | $106 |
| 99214 Office E&M - Established | Office | 785 | 233 | $100.79 | $79K |
| 99213 Office E&M - Established | Office | 712 | 288 | $64.56 | $46K |
| 96372 Injection Administration | Office | 331 | 122 | $11.39 | $3,769 |
| 96413 Chemotherapy Administration | Office | 306 | 78 | $103.46 | $32K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 301 | 160 | $13.26 | $3,992 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 300 | 11 | $0.71 | $214 |
| J3475 Injection, magnesium sulfate, per 500 mg | Office | 282 | 15 | $0.47 | $132 |
| 99232 Hospital E&M - Subsequent | Facility | 249 | 121 | $64.27 | $16K |
By year: 2022 $2.0M for 148,280 services; 2023 $3.4M for 196,156 services; 2024 $3.5M for 160,251 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 14 | 13 | $2.95 | $41.31 |
Medicare prescription drug claims, 2024
In 2024, the drug Rami Y Haddad prescribed most often to Medicare patients was Eliquis (Apixaban), with 204 prescriptions and refills. In total Rami Y Haddad wrote 1,702 Medicare prescriptions that cost $6.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 204 | 260 | 49 | $150K |
| Letrozole Generic | 150 | 369 | 43 | $2,549 |
| Anastrozole Generic | 113 | 309 | 39 | $2,060 |
| Revlimid Lenalidomide | 93 | 93 | Under 11 | $1.5M |
| Prednisone Generic | 83 | 93 | 32 | $418 |
| Dexamethasone Generic | 64 | 73 | 25 | $767 |
| Xarelto Rivaroxaban | 64 | 76 | Under 11 | $42K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 61 | 61 | 25 | $843 |
| Venclexta Venetoclax | 55 | 55 | Under 11 | $702K |
| Calquence Acalabrutinib Maleate | 52 | 52 | Under 11 | $765K |
| Duloxetine Hcl Generic | 51 | 89 | 19 | $811 |
| Allopurinol Generic | 41 | 67 | 12 | $253 |
| Ondansetron Hcl Generic | 40 | 40 | 26 | $279 |
| Prochlorperazine Maleate Generic | 28 | 28 | 20 | $253 |
| Levothyroxine Sodium Generic | 27 | 47 | Under 11 | $1,027 |
Brand drugs: 715 claims; generic drugs: 987 claims; opioid claims: 72.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rami Y Haddad $4,801 ($4,801 in general payments such as food, travel and fees) from 55 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $373.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 15 | $373 |
| Novartis Pharmaceuticals Corporation NVS | 19 | $334 |
| Pfizer Inc. PFE | 20 | $302 |
| Agios Pharmaceuticals, Inc. AGIO | 10 | $235 |
| GlaxoSmithKline, LLC. GSK | 11 | $232 |
| Merck Sharp & Dohme LLC MRK | 11 | $184 |
| Seagen Inc. PFE | 2 | $183 |
| Janssen Biotech, Inc. JNJ | 6 | $175 |
| Array Biopharma Inc PFE | 8 | $154 |
| Celgene Corporation BMY | 9 | $150 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.